878 results about "Toxin" patented technology

The invention relates to the technical field of artificial intelligence, and discloses a method and a system for dynamically predicting the risk of harm of feed mycotoxin to livestock and poultry. The method comprises the following steps: constructing a metabolic digital twin model based on a multi-organ coupling dynamics mechanism, connecting a gastrointestinal tract, a liver and a kidney through blood flow parameters to form a closed loop topology network, establishing a toxin migration rate equation, and verifying bioavailability; collecting feed toxin concentration and livestock and poultry physiological data in real time; after distributing the initial toxin load, iteratively generating target organ dynamic concentration distribution by adopting a Runge-Kutta method; an organ exposure index is calculated based on an organ specific hazard threshold, key organs are positioned, and low / high risk levels and toxin accumulation paths are output. The method solves the problems that a traditional static model is low in efficiency and poor in organ difference adaptability when being used for dynamically predicting the risk of harm to livestock and poultry caused by feed mycotoxin.

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.

The invention relates to an adjusting system applied to continuous kidney replacement treatment of acute kidney injury patients. Comprising the following steps: capturing the blood flow velocity and vascular endothelial permeability of glomerular capillaries in real time by using a micro sensor or a nano-scale optical imaging technology; the method comprises the following steps: pre-judging a risk time point of insufficient tissue perfusion through dynamic modeling of a capillary structure and a functional relationship; combining the microcirculation data with conventional biochemical indexes of the patient to create an early intervention model; when it is monitored that microcirculation perfusion is greatly reduced or kidney oxygen supply is insufficient, continuous renal replacement therapy CRRT parameter fine adjustment is triggered in advance; the method comprises the following steps: collecting plasma toxins of different patients at clinical and molecular levels, and constructing a common toxin map of the acute kidney injury AKI; whether the specific toxin concentration exceeds the standard or not is judged by combining a real-time sensor, and the removal priority is output in real time; a membrane material with an adjustable aperture or a special coating is adopted, so that inflammatory mediators and bacterial endotoxin molecules are adsorbed or intercepted, and the permeability of micromolecular electrolyte is kept.

The invention discloses lysinibacillus sp. For degrading alternaria alternata toxins and application of the lysinibacillus sp., and belongs to the technical field of microorganisms, the lysinibacillus sp. Is preserved in China Center for Type Microbiological Culture Collection, the preservation address is Wuhan University, Hubei Province, and the preservation number is CCTCC No.M20241816. The invention further discloses a preparation method of the lysinibacillus sp. According to the invention, the Lysinibacillus macroides capable of effectively reducing and degrading alternaria alternata toxin is obtained for the first time, and the quality of agricultural products (including aquatic products) is favorably improved.

The invention relates to streptomyces cell and application thereof in efficient degradation of aflatoxin B1, the streptomyces cell is streptomyces cell AFB1-D02, and has been preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33986, and the preservation date is March 26, 2025. The invention further discloses a preparation method of the streptomyces cell. The streptomycete S. cellostatus AFB1-D02 has the capability of efficiently degrading AFB1, and the degradation efficiency of the streptomycete S. cellostatus AFB1-D02 is obviously higher than that of other streptomycetes in the prior art.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

The disclosure provides an extracorporeal devices, systems and methods for removing a pathogen or a toxin from a biological fluid of a subject comprising contacting a biological fluid from the subject with a loosely packed bed of adsorption media, such as a fluidized bed, wherein the adsorption media comprises heparin, to remove the pathogen or the toxin to form a treated biological fluid; and infusing the treated fluid into the subject.

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.

The present application describes in part isolated and modified Enterococci toxin (Epx) polypeptides, immunogenic compositions comprising Exp polypeptides, nanopores formed by Epx polypeptides, apparatus comprising Epx nanopores, and methods of use thereof.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

The invention belongs to the technical field of bioengineering, and particularly relates to a zearalenone toxin degrading enzyme variant and application thereof. The amino acid sequence of the zearalenone toxin degrading enzyme is as shown in SEQ ID NO.2, or the zearalenone toxin degrading enzyme with the amino acid sequence as shown in SEQ ID NO.2 is obtained through amino acid mutation. The zearalenone toxin degrading enzyme mutant is obtained through mutation screening, and compared with a wild type, the zearalenone toxin degrading enzyme mutant has the advantages that the zearalenone degrading capability is obviously improved; besides, the zearalenone toxin degrading enzyme is expressed by using alfalfa, the zearalenone toxin degrading enzyme with biological activity is easy to obtain, and the zearalenone toxin degrading enzyme has certain application potential in prevention and treatment of animal poisoning caused by zearalenone toxin pollution in agriculture and animal husbandry production.

This invention is related to the field of biosensors. In particular, devices and methods are described which enable the quantification of biomolecules by virtue of particle speed driven by induced-charge electrophoresis. For example, a range of biomolecules can be simultaneously detected in a highly sensitive manner from a library (e.g., combination) of active particles having different shapes or fluorescent signatures. Such biomolecules are related to conditions including, but not limited to, cancer biomarkers, viral infection biomarkers, toxins, pesticides, and small molecule drugs.

The invention discloses a colorimetric aptamer sensor and application thereof, and belongs to the technical field of biological detection. The colorimetric aptamer sensor comprises Cas12a protein, HP, crRNA, dsDNA (double-stranded deoxyribonucleic acid) and a colorimetric probe. The colorimetric biosensor is applied to detection of the ochratoxin A, the content of the ochratoxin A is detected through the colorimetric biosensor, and detection and analysis of a target object can be achieved; cas12a aptamer inhibitors are developed as molecular switches for biosensors, which mediate target recognition through engineering modification of HP hairpin sequences. A new thought for improving the mycotoxin detection sensitivity is explored, and good detection potential is expected to be shown in the field of food safety.

The invention relates to the technical field of biology, and particularly discloses a recombinant protein for improving the curative effect of an ADC drug and application of the recombinant protein. The recombinant protein comprises a tumor cell surface targeting structure, a cell transmembrane structure and toxin molecules, the toxin molecule is connected and fused with the tumor cell surface targeting structure and / or the cell transmembrane structure; the tumor cell surface targeting structure is a protein structure capable of being specifically combined with a tumor cell surface target spot; and the cell penetrating structure is a protein structure for mediating the recombinant protein to penetrate through a cell membrane to enter the cell. The tumor cell surface targeting structure is used for specifically recognizing a target cell surface target spot, the killing activity of a conventional antibody is brought into play, then toxin molecules are brought into tumor cells through the cell transmembrane structure, toxin is released, the tumor killing effect is achieved, the ADC drug curative effect is improved, and the ADC drug application prospect is wide. The transmembrane efficiency of the cell transmembrane structure can be improved to 50-90%, so that the traditional ADC drug treatment window is improved.

The invention discloses a method for inhibiting production of vomitoxin from bacillus cereus, which is characterized in that isoleucine is added into a substance needing to inhibit production of vomitoxin from bacillus cereus, preferably 5-20mM of isoleucine is added. According to the present invention, the content of the toxin is detected through the liquid chromatography-mass spectrometry, and the cytotoxicity experiment verification results show that the isoleucine can significantly inhibit the synthesis of the vomitoxin of the bacillus cereus in the culture medium and the matrix, and can effectively reduce the toxic effect of the toxin on HeLa cells; the invention provides a safe and efficient biological control means which is suitable for various food systems such as starch food, dairy products, meat products and the like. Isoleucine can be used as a novel non-toxic and harmless food additive and is low in cost; the use method is simple, the output of vomitoxin can be reduced by directly adding a trace amount of isoleucine, and the food flavor is not affected.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a bezoar intermediate and a preparation method of bezoar. The preparation method comprises the following steps: mixing preparation raw materials and biochemical reaction liquid to obtain a mixed raw material solution; the preparation raw materials comprise bilirubin, organic active raw materials and vitamins, the biochemical reaction liquid is sterile purified water, and the bilirubin comprises bilirubin or biliverdin; and reacting the mixed raw material solution to obtain the bezoar intermediate. The content of combined bilirubin in the bezoar intermediate prepared by the preparation method provided by the invention is 75%-85%, the content of combined biliverdin is 73%-83%, and the yield is 83%-87%. According to the method, the poisoning and destroying effects of mycotoxin on the content, the yield, the biological activity and the oxidation resistance of the bezoar intermediate are effectively eliminated. The content, the yield, the oxidation resistance and the biological activity of the bezoar intermediate are greatly improved, the performance is stable, and the quality of bezoar is ensured.

The invention belongs to the technical field of enzyme engineering, and particularly relates to a codon optimized superoxide dismutase AfSOD gene and application thereof in degradation of aflatoxin B1 and zearalenone. Under the conditions that the pH is 7, the temperature is 40 DEG C and the enzyme addition amount is 10 micrograms, the degradation rate of the AFB1 reaches 99.08% within 24 hours, and the degradation rate is kept to be 80% or above within 40-80 DEG C; under the conditions that the pH is 8, the temperature is 60 DEG C and the enzyme addition amount is 20 micrograms, the degradation rate of ZEN reaches 85.1% in 24 hours, and the degradation rate is kept to be 80% or above within 50-80 DEG C; the result shows that AfSOD is a toxin degrading enzyme which can tolerate a certain degree of high temperature; the degradation rates of AFB1 and ZEN in polluted peanut powder or corn powder are 73.7% and 88.2% respectively; the invention provides a new candidate for detoxification of AFB1 and ZEN in food or feed, and has a good application prospect.

The invention discloses a detection product and method for detecting botulinum toxin type A component protein. The detection product provided by the invention comprises an antibody capable of specifically recognizing the botulinum toxin type A component protein. The antibody disclosed by the invention has good affinity and stability, can be widely applied to detection of botulinum toxin component protein A, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detecting botulinum toxin component antibodies, and provides a quality control means for commercialized and self-researched antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.

The present invention provides a botulinum toxin protein composition, mainly comprising botulinum toxin protein, a saccharide, a salt, and human serum albumin. The botulinum toxin protein composition of the present invention features good activity and stable properties, and can maintain the activity of the botulinum toxin protein at a high level after long-term storage.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, e.g., a camptothecin cytotoxic molecule which is cell-permeable; as a second payload a topoisomerase I inhibitor which is not cell-permeable, e..g., a camptothecin cytotoxic molecule which is not cell-permeable; and as a as a third payload a toxin or a cytotoxin, e.g., an auristatin such asMMAE (Monomethyl auristatin E). Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention discloses a composition containing probiotics and fusion polypeptide and application of the composition in treatment of intestinal inflammatory diseases. The composition is prepared from lactobacillus plantarum (Lactobacillus plantarum CCFM8661) and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the composition. The fusion polypeptide can be used for directly inhibiting the growth of pathogenic bacteria and neutralizing toxins by enhancing the intestinal colonization capability of probiotics, so that the triple synergistic effect of bacteriostasis, repair and immunoregulation is realized. Experiments show that the composition significantly reduces the disease activity index in a DSS-induced mouse colitis model, recovers the colon length, and inhibits serum inflammatory factors IL-6 and TNF-alpha. In addition, the survival rate of the freeze-dried microcapsule preparation in simulated gastric juice is gt; the colon targeted release characteristic is realized. The invention provides an efficient and stable new treatment strategy for intestinal inflammatory diseases.

The invention relates to the technical field of pomacea canaliculata trapping, killing and preventing, in particular to an efficient pomacea canaliculata trapping and killing method which comprises the following steps: pre-treating drug particles, specifically preparing drug particles for storing trapping and killing drugs, thickening duckweed dry powder, specifically, coating the drug particles with a duckweed dry powder coating with the thickness of 1mm to obtain inner sphere particles, the mikania micrantha ethanol dry powder thickening treatment means that the mikania micrantha ethanol dry powder tightly and uniformly covers the surface of the duckweed dry powder coating by adopting a spraying process on the outer layer of the inner sphere particles. According to the method, the pomacea canaliculata is actively induced to gather and feed by utilizing the rape straw pith core, and aquatic / terrestrial plant wastes are converted into a biological carrier with gradient inducing-poisoning functions; natural toxic components of mikania micrantha are used for replacing traditional chemical pesticides; the straw pith core is used as a universal skeleton, the duckweed dry powder plays the functions of ecological attraction and nutrition supplement, the mikania micrantha ethanol dry powder provides efficient poisoning ability, and the method is especially suitable for green prevention and control of ampullaria gigas in rice cropping areas of the Yangtze River basin.

The invention discloses a detection method for detecting botulinum toxin A HA-70 and a product. The detection product disclosed by the invention comprises an antibody capable of being combined with the botulinum toxin A HA-70. The antibody has good affinity and stability, can be widely applied to detection of botulinum toxin type A HA-70, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detection of botulinum toxin component antibodies, and provides a quality control means for commercialization and self-research of antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.

The invention discloses a kit, an antibody and a method for detecting A-type botulinum toxin hemagglutinin-70. The kit of the present invention comprises an antibody capable of targeting type A botulinum toxin hemagglutinin-70. The antibody disclosed by the invention has good affinity and stability, can be widely applied to detection of A-type botulinum toxin hemagglutinin-70, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detecting botulinum toxin component antibodies, and provides a quality control means for commercialized and self-researched antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.

Disclosed herein are methods for detecting virulent Shiga toxin-producing E. coli (STEC) strains O26, O103, O121, and O111 in a biological sample comprising the steps of: (i) enriching the bacterial concentration of the biological sample to result in an enriched sample; (ii) isolating DNA from said enriched biological sample; and (iii) detecting virulent strain in said isolated DNA sample via real-time PCR and a melt curve assay. Also disclosed are primers for said assay, as well as kits comprising said primers.

The invention belongs to the technical field of microbial fermentation and insect pest prevention and control, and particularly relates to endogenous bacillus velezensis and application of fermentation liquor of the endogenous bacillus velezensis in prevention and control of bemisia tabaci. The invention discloses bacillus velezensis NM153 which is preserved in the China Center for Type Culture Collection on March 27, 2025, and the preservation number of the bacillus velezensis NM153 is CCTCC (China Center for Type Culture Collection) M 2025605. A stock solution of the bacillus velezensis NM153 supernate and the bacterial suspension is diluted by 300 times and 500 times to treat the bemisia tabaci, and the result shows that the death rate of the bemisia tabaci treated by the bacillus velezensis NM153 supernate is obviously higher than that of a bacterial suspension treatment group, and the death rate of the bemisia tabaci treated by the bacterial suspension treatment group is obviously higher than that of the bemisia tabaci treated by the bacillus velezensis NM153. In addition, the bacillus velezensis NM153 metabolite is further verified and explained to have a remarkable technical effect on preventing and treating bemisia tabaci in o-carboxybenzaldehyde, tenuitoxin and micronomicin in the bacillus velezensis NM153 metabolite.

Multi-modal, modular biosensing and sterilization systems and methods for detection and neutralization of pathogens, toxins, and contaminants, and integrating coordinated agents and dispensers therefor for decontamination. The systems and methods are operable as closed-loop or cloud-connected platforms, and can be configured for communication with health and authorities for reporting and tracking.

The present disclosure is directed toward drugs or toxins; drug conjugates comprising said drugs or toxins and a cleavable linker; and conjugates comprising said drugs or toxins, cleavable linkers, and cell-binding groups. The present disclosure also relates to methods of treating cancers, autoimmune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

The invention discloses a Trichoderma reesei strain and an application of the Trichoderma reesei strain in degradation of mycotoxin and inhibition of toxin-producing bacteria. The Trichoderma reesei strain is a Trichoderma reesei strain GG-T40, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: M20231843. The strain can synchronously and efficiently degrade eight kinds of mycotoxins such as AFB1, ZEN, T-2, ST, OTA, AOH, AME and TeA, and after the strain and the mycotoxins are co-cultured for 7 days, the removal rates of the eight kinds of toxins are all larger than or equal to 60%. The strain has strong bacteriostasis and toxin production inhibition effects, the toxin production inhibition rates of the strain to aspergillus flavus and fusarium graminearum are 62.5% and 74.4% respectively, and the strain can be applied to degradation of mycotoxin in agricultural products and food and inhibition of mildew and toxin production of the agricultural products and food.